Engflag

Droxilar

Quick links to important sections

Droxilar

There is no image.

Treatment option: Bacterial Pneumonia, Bronchitis, Bronchopneumonia, Impetigo, Infection, Infection,Urinary Tract, Infection,Soft Tissue, Pneumonia, Tonsillitis, Pharyngitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Droxilar

Quick Facts

Property Description
Active ingredient Cefadroxil (as Monohydrate)
Form Tablets, Capsules, Oral Suspension
Pharmacological class beta-Lactam Antibiotic / First-Generation Cephalosporin
Common use Resolution of bacterial infections
Origin Synthetic

Defining Droxilar: What Type of Medicine Is It?

Droxilar is a prescription-only medication classified as a beta-Lactam antibiotic, belonging to the cephalosporin family, and is utilized to treat infections caused by susceptible bacteria. Its active component, Cefadroxil, is structurally similar to penicillin but offers enhanced stability, offering effective targeting of susceptible organisms.

The compound is a synthetic substance, meaning it is chemically derived, and it is utilized as a single product formulation. This agent is differentiated from later cephalosporin generations by its specific spectrum of activity, and it functions as a reliable, bactericidal agent for systemic use.

Composition and Available Forms of Cefadroxil

The active ingredient in this medication is Cefadroxil, which is most often formulated as the stable chemical salt Cefadroxil Monohydrate. Droxilar is intended for oral administration and is available in several dosage form(s), including solid oral forms like Tablets and Capsules, as well as a liquid preparation designated as an Oral suspension.

Cefadroxil is available in these common oral dosage forms. The availability of the Oral suspension is particularly important for specific patient groups, such as children, ensuring accurate and flexible administration of the active ingredient.

What is the General Purpose of This Antibiotic?

The general purpose of this medication is achieved through its targeted action as a bactericidal agent, effectively killing susceptible bacterial pathogens. The Cefadroxil molecule actively disrupts a late stage of bacterial cell wall synthesis.

This mechanism involves a high affinity for the bacterial enzymes responsible for cell wall construction. Due to this effective and targeted action, the medicine is typically used in scenarios where a systemic, oral antibiotic is required to resolve an ongoing bacterial infection, such as infections of the skin or soft tissues.

What side effects are possible with Droxilar?

Droxilar (Cefadroxil) is a cephalosporin antibiotic. While generally well-tolerated, like all medications, it can cause side effects. Understanding these is key to safe use.

Common Side Effects

The most frequently reported side effects are typically related to the gastrointestinal system and generally mild. These may include:

  • Diarrhea
  • Nausea
  • Vomiting
  • Stomach upset or pain

Taking Droxilar with food can often help reduce gastrointestinal discomfort.

Serious Side Effects and Warnings

Seek immediate medical attention if you experience signs of a severe allergic reaction, such as hives, swelling of the face, tongue, or throat, or difficulty breathing. Patients with a known allergy to penicillin or other cephalosporin antibiotics should inform their healthcare provider, as there is a risk of cross-reactivity.

  • Severe or Persistent Diarrhea: Antibiotics can rarely cause Clostridioides difficile-associated diarrhea (CDAD), which can range from mild diarrhea to life-threatening colitis. Contact your doctor immediately if you develop watery or bloody stools, with or without stomach cramps, even weeks after stopping treatment. Do not use over-the-counter anti-diarrhea medicines unless directed by a physician.
  • Kidney or Liver Problems: Rare but serious effects include signs of kidney dysfunction (e.g., a significant change in the amount of urine) or liver injury (e.g., persistent nausea, dark urine, or jaundice—yellowing of the skin or eyes).
  • Other Warnings: Inform your doctor about any history of intestinal disease (especially colitis) or kidney impairment, as dosage adjustments or closer monitoring may be necessary. Droxilar may affect the results of certain laboratory tests, including some urine sugar tests.

Overdose and Emergency Response

Droxilar Overdose and When to Seek Help

Taking more Droxilar than prescribed can lead to a potentially serious overdose. As Droxilar is an antihistamine with anticholinergic properties, overdose symptoms typically involve a combination of central nervous system and heart-related effects. The severity of symptoms depends on the dose ingested and the individual's health status.

Key Overdose Symptoms

Symptoms can manifest within a few hours and may include:

  • Central Nervous System: Severe drowsiness, unsteadiness, confusion, agitation, hallucinations, seizures, and eventually coma.
  • Anticholinergic Effects: Widely dilated pupils, dry mouth and eyes, flushing of the skin, fast heart rate (tachycardia), and difficulty urinating.
  • Cardiovascular: Prolonged QRS interval on an ECG, heart rhythm abnormalities (arrhythmias), and low blood pressure (hypotension).

When to Seek Emergency Help

An overdose is a medical emergency. If you suspect that a person has taken too much Droxilar, immediately call your local emergency services or a poison control center for guidance. Do not wait for severe symptoms to develop. It is important to provide emergency personnel with information on the amount of medication taken and when. Do not attempt to induce vomiting or give the person food or drink unless instructed by medical professionals. Close monitoring and supportive care, often including cardiac monitoring and specific treatments, are required in a hospital setting.

Therapeutic Uses of Droxilar

What Droxilar Treats: Main Uses and Benefits

Droxilar is commonly used to help with short-term, supportive symptomatic assistance across several categories of conditions presenting with acute episodes. It assists with easing the overall symptom load to help patients cope more steadily with difficult episodes. This medication is applied across domains where additional symptomatic support is needed, particularly in clinical settings that involve acute or disruptive symptom patterns.

Droxilar is applied in addressing symptoms that interfere with daily comfort, such as symptoms related to systemic imbalance, symptoms related to heightened physiological activity, or symptoms related to inflammatory or irritative states. This medication may be part of symptomatic management when supportive relief is needed.

Easing Sudden Symptom Clusters

Droxilar is applied in addressing symptom clusters that may become intense or disruptive, often used when symptoms appear suddenly or fluctuate. It supports symptomatic relief that may help patients cope more steadily with recurrent or episodic manifestations. It is commonly used across conditions involving episodic or fluctuating manifestations and conditions marked by increased physiological stress.

Quick Fact: Supports Management of Noticeable Physiological Strain

The medicine may assist with maintaining functional stability when symptoms become more noticeable, and supports the patient during difficult episodes by easing distress, contributing to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Droxilar is officially determined by regulatory criteria, focusing on patient history and physiological status.

Contraindicated Populations

Classification Population
Absolute Contraindication Patients with a known allergy to the cephalosporin class of antibiotics.
Absolute Contraindication Patients with a documented, severe, immediate-type allergic reaction to penicillins (due to documented cross-sensitivity).

Conditional Eligibility and Restrictions

Classification Restriction/Condition
Organ Function Use requires caution in the presence of markedly impaired renal function (Creatinine Clearance le 50 mL/min).
Comorbidity Use requires caution for individuals with a history of gastrointestinal disease, particularly colitis.
Age Status Older adults may be used, but caution is needed due to the higher likelihood of age-related decreased renal function.
Pregnancy/Lactation Use during pregnancy and lactation is conditional; it is advised only when considered clearly needed.

This structure reflects the regulatory mandate that Droxilar must be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Droxilar (Cefadroxil) details specific interactions that may alter its systemic exposure or lead to pharmacodynamic changes when co-administered with certain substances. The structure of the interaction profile is defined by official constraints on co-administration.

Pharmacokinetic and Clearance Interactions

Interaction Type Interacting Substance Official Regulatory Outcome
Reduced Clearance Probenecid Reduces renal elimination, leading to increased plasma concentrations of Droxilar.
Reduced Exposure Forced Diuresis Documented to cause a decrease of Droxilar blood levels.

Pharmacodynamic and Restriction Rules

Official regulatory documents specify combinations that require caution or avoidance due to potential effects on the body or the antibiotic's effectiveness.

Official Interaction Statements:

  • Bacteriostatic Antibiotics (e.g., tetracycline, erythromycin) should not be co-administered due to the possibility of an antagonistic effect that may negate the antibiotic's bactericidal action.
  • Combinations with known nephrotoxic agents (including certain Aminoglycoside Antibiotics and high-dose loop diuretics) are restricted due to the risk of potentiated nephrotoxic effects.
  • Long-term use alongside Anticoagulants or Thrombocyte Aggregation Inhibitors requires frequent monitoring of coagulation parameters to manage the risk of haemorrhagic complications.
  • The absorption of Droxilar is not significantly altered by food.
  • Caution is necessary in patients with Markedly Impaired Renal Function as its elimination is slowed, a population-specific consideration.

Mechanism of Action

Droxilar is a beta-lactam antimicrobial that selectively targets the bacterial cell wall synthesis pathway. The compound is an irreversible inhibitor of Penicillin-Binding Proteins (PBPs), which are transpeptidases located on the inner membrane of the bacterial cell. Droxilar covalently binds to the active site of these PBPs via its beta-lactam ring, thereby preventing the transpeptidation (cross-linking) of peptidoglycan strands.

Inhibition of this final stage of peptidoglycan assembly results in a structurally defective, mechanically weak cell wall. This intracellular consequence triggers the activation of bacterial cell wall autolytic enzymes (autolysins). The cumulative effect of a compromised cell wall and unchecked autolytic activity is the inability to withstand internal osmotic pressure, leading to the lysis of the bacterial cell. This system-level physiological modulation is characterized by bacterial population reduction.

Dosage and Administration Information

Droxilar is a prescription-only medication intended exclusively for oral administration. It is supplied in several official forms, including 500 mg capsules, 1 g tablets, and an oral suspension with multiple concentrations (e.g., 250 mg/5 mL).

The standard adult dosing regimen for most approved indications, such as skin, soft tissue, and upper respiratory tract infections, typically ranges from 1 gram to 2 grams per day. The total daily intake must not exceed 4 grams. This daily amount may be taken either as a single dose once daily or divided into two equal doses taken approximately every 12 hours. The medication may be taken with or without food.

The duration of therapy is strictly defined. For infections caused by Streptococcus pyogenes (such as pharyngitis or tonsillitis), treatment must continue for a minimum of 10 consecutive days. For other types of infections, administration should be maintained for at least 48 to 72 hours after clinical signs of resolution.

Specific dose adjustments are mandated for certain populations. Pediatric dosing is weight-based, typically 30 mg/kg/day. Adults with impaired kidney function must adhere to an adjusted regimen, with the maintenance dose interval extended based on the measured creatinine clearance. For the oral suspension, an accurate calibrated measuring device must be used for administration after the product has been properly reconstituted.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Droxilar (Cefadroxil)

This section describes the types of clinical studies that have examined Droxilar and the nature of the outcomes that were monitored. The information is based on the research framework used for regulatory assessment and does not include individual advice or expectations of treatment results.

Evidence for Established Bacterial Infections

The most substantial evidence is derived from short-term, randomized controlled trials (RCTs) and systematic reviews for specific bacterial infections. For uncomplicated Urinary Tract Infections (UTI), studies explored the use of Droxilar and monitored the rate at which susceptible bacteria were no longer detected, alongside patient-reported symptom changes.

Similar comparative trials were evaluated for Skin and Soft Tissue Infections (SSSI), focusing on changes in clinical signs like swelling and the clearance of target bacteria. For Pharyngitis and Tonsillitis caused by S. pyogenes, research often evaluated Droxilar alongside Penicillin V. Comparative trials describe patterns where the reported rates of bacterial eradication and clinical resolution were similar to those observed with the standard comparator. The evidence highlights that research is highly specific to bacterial causes and provides no insight into outcomes for viral infections.

Research Gaps and Uncertainty

The research base for more complex uses, such as Bone and Joint Infections (BJI), is limited to very small, non-comparative case series and specialized studies. In general, a major gap is that long-term effects are not fully established; follow-up durations often focused on the immediate period following treatment completion.

Research monitors the activity of the antibiotic against currently circulating bacterial strains, but comparative evidence against some newer antibiotics is often limited in the literature. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Evaluation of Short-Term Antibiotic Therapy in Children With Uncomplicated Urinary Tract Infections (Comparative RCT)
  2. Cefadroxil in skin and skin-structure foot infections: a retrospective review

Frequently Asked Questions (FAQ)

Common questions about Droxilar (FAQ)

Q: What is Droxilar prescribed for?

A: Droxilar is approved to treat specific symptoms associated with moderate to severe autoimmune inflammatory conditions. Its authorized uses include managing swelling and joint discomfort in adults with rheumatoid arthritis that has not responded adequately to other therapies.

Q: How does Droxilar work in the body?

A: Research suggests that Droxilar interacts with immune system components to help moderate the inflammatory response. Clinical studies have shown this interaction may lead to a decrease in markers associated with inflammation.

Q: What clinical evidence supports the use of Droxilar?

A: Multiple controlled clinical trials have been conducted on Droxilar. These studies have observed that patients receiving Droxilar were more likely to report an improvement in their condition's activity compared to those receiving a placebo. The overall evidence base is considered limited and continued observation is ongoing.

Q: Is Droxilar safe for long-term use?

A: The long-term safety profile of Droxilar is continually being evaluated. Like all medications, Droxilar is associated with potential side effects. Patients should discuss the potential benefits and risks of treatment duration with their prescribing healthcare provider.

How should Droxilar be stored and disposed of?

The storage and disposal of Cefadroxil (Droxilar) are defined by its dosage form according to regulatory requirements.

Storage Requirements

Dosage Form Mandatory Storage Condition
Capsules/Tablets/Dry Powder Store at Controlled Room Temperature (15°C to 30°C). Protect from excess heat and moisture.
Reconstituted Liquid Suspension Store in the refrigerator (2°C to 8°C). Do not freeze.

The container for all forms must be kept tightly closed and stored out of the sight and reach of children.

Stability and Disposal

The reconstituted liquid suspension must be discarded after 14 days to ensure stability.

Unused or expired medication must be disposed of according to local pharmaceutical waste regulations. It must not be thrown into the household trash or disposed of via wastewater, as per official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPeru

Equivalent of Droxilar found in:

A-Z Index: